tickrz reports
Alexion Pharmaceuticals Inc (ALXN)
Healthcare | Drugs
122.71  0.19%
ALXN vs DRUGS SECTOR & S&P 500
VALUATION
ALXNSECTORS&P 500
P/E RATIO54.5640.521.12
EV/EBITDA RATIO27.79133.412.66
P/S RATIO7.956.52.25
P/B RATIO3.097.73.45
QUALITY
RETURN ON EQUITY5.8%15.79%13.64%
RETURN ON CAPITAL5.42%19.38%10.09%
NET MARGIN13.25%14.46%9.73%
DIVIDEND ANALYSIS
DIVIDEND YIELD
0%
PAYOUT RATION/A
3 YR DIVIDEND GROWTHN/A
FINANCIAL STRENGTH
PIOTROSKI F SCORE
6 OUT OF 9
DEBT-TO-EQUITY36%
INTEREST COVERAGE9x
CURRENT RATIO2.97
GROWTH
5 YR EPS GROWTH14.1%
5 YR SPS GROWTH30.68%
5 YR BPS GROWTH44.71%
Alexion Pharmaceuticals Inc News
The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex
For Immediate Release Chicago IL January 12 2018 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
January 12, 16:09:16 UTC

The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex
The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex
January 12, 14:16:02 UTC

ALXN March 2nd Options Begin Trading
Investors in Alexion Pharmaceuticals Inc Symbol ALXN saw new options become available today for the March 2nd expiration At Stock Options Channel our YieldBoost formula has looked up and down the ALXN options chain for the new March 2nd contracts and identified one put and one
January 11, 17:06:11 UTC

Can Biotech Keep Last Year's Momentum Alive in 2018?
The year 2017 has been better than expected for the biotech sector The NASDAQ Biotechnology index was up 18 7 in 2017 While drug pricing issue competition and a slowdown in growth of key drugs are expected to remain a hangover in 2018 as well approval of new drugs and strategic acquisitions
January 11, 17:02:47 UTC

How Mylan’s North America Segment Performed in 3Q17
Who’s Watching Mylan in January 2018?
January 10, 20:05:02 UTC

A Look at Ionis Pharmaceuticals’ January 2018 Valuation
What's the Word on Ionis Pharmaceuticals This January?A look at Ionis Pharmaceuticals
January 10, 19:35:13 UTC

How’s Incyte’s Valuation in January 2018?
New Insights for Incyte Corporation as of JanuaryA look at Incyte
January 09, 15:23:32 UTC

See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.
Alexion Pharmaceuticals Inc NASDAQ/NGS:ALXN
January 09, 13:01:44 UTC

10 Strong Buy Stocks From 2017’s Best Analysts
InvestorPlace Stock Market News Stock Advice amp Trading Tips What are the top analysts who consistently get it right recommending strong buy stocks for 2018 TipRanks tracks and measures the performance of over 4 700 analysts to 160 identify the top experts in each sector 160
January 09, 01:02:54 UTC

How To Trade The JPMorgan Healthcare Conference
The JPMorgan Healthcare Conference, one of the biggest and most important events of the year for biotech investors, kicks off this week. Last week, Morgan Stanley analyst Matthew Harrison compiled a report ...
January 08, 18:19:04 UTC

S&P 500 Analyst Moves: ALXN
The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S amp P 500 index Alexion Pharmaceuticals ALXN is now the 26 analyst pick moving up by 1 spot This rank is formed by averaging the analyst opinions for each component from
January 08, 18:02:13 UTC

Implied FBT Analyst Target Price: $151
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
January 08, 15:06:01 UTC

Omeros Inks Agreement With FDA for OMS721 Phase III Trial
Omeros Corporation OMER announced that it has entered into an agreement with the FDA on its protocol to start a phase III study to evaluate its lead pipeline candidate OMS721 for treatment of patients with IgA nephropathy IgAN Enrollment of patients for the study is expected to start
January 04, 17:14:51 UTC

Sorry Alexion! Biotech Rally Will Leave You Behind
Raymond  James's Laura Chico takes a look at the biotech landscape for 2018, writing that she's optimistic about the sector, although she's cooled a bit on Alexion Pharmaceuticals (ALXN). Chico writes that regulatory agencies are working "efficiently" to facilitate drug approvals, and the proof was in the pudding, given last year's record number of approvals. Some picks from her note: Heading into 2018, we think the mid-cap space appears attractive, particularly as players like Sage Therapeutics (SAGE), Ultragenyx Pharmaceutical (RARE), and Blueprint Medicines Corporation (BPMC) advance late-stage assets closer to the commercial stage.
January 04, 15:40:00 UTC

5 Stock Winners From Wall Street's Top Analysts
From the five equity analysts with the best track records in 2017 come these five stock picks.
January 04, 13:00:00 UTC


Alexion Pharmaceuticals Inc (ALXN)
Healthcare | Drugs
122.71  0.19%

The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex
For Immediate Release Chicago IL January 12 2018 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
January 12, 16:09:16 UTC

The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex
The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex
January 12, 14:16:02 UTC

ALXN March 2nd Options Begin Trading
Investors in Alexion Pharmaceuticals Inc Symbol ALXN saw new options become available today for the March 2nd expiration At Stock Options Channel our YieldBoost formula has looked up and down the ALXN options chain for the new March 2nd contracts and identified one put and one
January 11, 17:06:11 UTC

Can Biotech Keep Last Year's Momentum Alive in 2018?
The year 2017 has been better than expected for the biotech sector The NASDAQ Biotechnology index was up 18 7 in 2017 While drug pricing issue competition and a slowdown in growth of key drugs are expected to remain a hangover in 2018 as well approval of new drugs and strategic acquisitions
January 11, 17:02:47 UTC

How Mylan’s North America Segment Performed in 3Q17
Who’s Watching Mylan in January 2018?
January 10, 20:05:02 UTC

A Look at Ionis Pharmaceuticals’ January 2018 Valuation
What's the Word on Ionis Pharmaceuticals This January?A look at Ionis Pharmaceuticals
January 10, 19:35:13 UTC

How’s Incyte’s Valuation in January 2018?
New Insights for Incyte Corporation as of JanuaryA look at Incyte
January 09, 15:23:32 UTC

See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.
Alexion Pharmaceuticals Inc NASDAQ/NGS:ALXN
January 09, 13:01:44 UTC

10 Strong Buy Stocks From 2017’s Best Analysts
InvestorPlace Stock Market News Stock Advice amp Trading Tips What are the top analysts who consistently get it right recommending strong buy stocks for 2018 TipRanks tracks and measures the performance of over 4 700 analysts to 160 identify the top experts in each sector 160
January 09, 01:02:54 UTC

How To Trade The JPMorgan Healthcare Conference
The JPMorgan Healthcare Conference, one of the biggest and most important events of the year for biotech investors, kicks off this week. Last week, Morgan Stanley analyst Matthew Harrison compiled a report ...
January 08, 18:19:04 UTC

S&P 500 Analyst Moves: ALXN
The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S amp P 500 index Alexion Pharmaceuticals ALXN is now the 26 analyst pick moving up by 1 spot This rank is formed by averaging the analyst opinions for each component from
January 08, 18:02:13 UTC

Implied FBT Analyst Target Price: $151
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
January 08, 15:06:01 UTC

Omeros Inks Agreement With FDA for OMS721 Phase III Trial
Omeros Corporation OMER announced that it has entered into an agreement with the FDA on its protocol to start a phase III study to evaluate its lead pipeline candidate OMS721 for treatment of patients with IgA nephropathy IgAN Enrollment of patients for the study is expected to start
January 04, 17:14:51 UTC

Sorry Alexion! Biotech Rally Will Leave You Behind
Raymond  James's Laura Chico takes a look at the biotech landscape for 2018, writing that she's optimistic about the sector, although she's cooled a bit on Alexion Pharmaceuticals (ALXN). Chico writes that regulatory agencies are working "efficiently" to facilitate drug approvals, and the proof was in the pudding, given last year's record number of approvals. Some picks from her note: Heading into 2018, we think the mid-cap space appears attractive, particularly as players like Sage Therapeutics (SAGE), Ultragenyx Pharmaceutical (RARE), and Blueprint Medicines Corporation (BPMC) advance late-stage assets closer to the commercial stage.
January 04, 15:40:00 UTC

5 Stock Winners From Wall Street's Top Analysts
From the five equity analysts with the best track records in 2017 come these five stock picks.
January 04, 13:00:00 UTC